Trial Profile
Effect of Repeated Oral Doses of BI 1060469, BI 1021958 and Active Controls, Cimetidine and Naproxen, on Measured GFR Via Renal Clearance of Iohexol in Healthy Male Subjects (a Phase I Study; Single-blind, Randomized, Placebo-controlled Within BI Groups and Open-label for the Active Controls)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs BI 1021958 (Primary) ; BI 1060469 (Primary) ; Cimetidine; Naproxen
- Indications Asthma
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 23 Dec 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 21 Sep 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 14 Aug 2014 Planned End Date changed from 1 Dec 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov record.